Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Background Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep
veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background Pulmonary embolism is a potentially life‐threatening condition in which a clot
can travel from the deep veins, most commonly in the leg, up to the lungs. Previously, a …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …

ABSTRACT Introduction Direct oral anticoagulants (DOACs) have overtaken vitamin K
antagonists to become the most widely used method of anticoagulation for most indications …

Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …